Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Video

Updated: Jun 14, 2026

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Published on: November 5, 2019

Hydroxyurea therapy requires HbF induction for clinical benefit in a sickle cell mouse model.

Jeffrey D Lebensburger¹, Tamara I Pestina, Russell E Ware

¹Department of Hematology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

|April 10, 2010

Summary

Hydroxyurea benefits sickle cell disease (SCD) patients, but its mechanism was unclear. This study shows fetal hemoglobin induction, not other effects, is key to hydroxyurea

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Seroprotection after Measles Vaccination in Children with Sickle Cell Anemia Receiving Hydroxyurea.

Blood advances·2026

Same author

Hydroxyurea interferes with point-of-care creatinine testing in children with sickle cell anemia.

BMC research notes·2026

Same author

Ten Years of Hydroxyurea for Ugandan Children with Sickle Cell Anemia.

The New England journal of medicine·2026

Same author

Persistent Splenomegaly Is Associated with Morbidity in Tanzanian Children with Sickle Cell Anemia: Secondary Analysis of the SPHERE Trial.

Acta haematologica·2026

Same author

Growth and puberty in African children with sickle cell anemia treated with hydroxyurea.

Blood advances·2026

Same author

Sickle Cell Disease in Sub-Saharan Africa: Progress and Potential.

American journal of hematology·2026

Area of Science:

Hematology
Genetics
Pharmacology

Background:

Sickle cell disease (SCD) is a debilitating genetic blood disorder.
Hydroxyurea is a standard treatment for SCD, improving clinical outcomes.
The exact mechanisms behind hydroxyurea's efficacy, particularly fetal hemoglobin (HbF) induction, are still under investigation.

Purpose of the Study:

To investigate the role of fetal hemoglobin induction as the primary mechanism for hydroxyurea's therapeutic benefits in sickle cell disease.
To differentiate the effects of HbF induction from other potential mechanisms of hydroxyurea, such as reduced neutrophil and platelet counts.

Main Methods:

Utilized a murine model of sickle cell disease specifically engineered to prevent HbF induction by hydroxyurea.
Administered a maximally tolerated dose of hydroxyurea to assess hematologic parameters and end-organ damage.

More Related Videos

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

Related Experiment Videos

Last Updated: Jun 14, 2026

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Characterization of Sickling During Controlled Automated Deoxygenation with Oxygen Gradient Ektacytometry

Published on: November 5, 2019

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Endothelialized Microfluidics for Studying Microvascular Interactions in Hematologic Diseases

Published on: June 22, 2012

Compared outcomes with control mice and with mice that received gene therapy to induce high HbF levels.

Main Results:

Hydroxyurea treatment in the murine model did not improve hemolytic anemia or reduce end-organ damage, despite significant reductions in neutrophil and platelet counts.
Mice achieving high HbF levels through gamma-globin lentiviral vector gene transfer showed corrected anemia and organ damage.
These findings indicate that HbF induction is critical for therapeutic benefits.

Conclusions:

The beneficial effects of hydroxyurea in sickle cell disease are primarily mediated by the induction of fetal hemoglobin.
Other potential mechanisms of hydroxyurea, such as effects on neutrophils and platelets, do not appear to be sufficient for therapeutic improvement in this model.
These results underscore the importance of targeting HbF induction for effective sickle cell disease therapies.